Works matching AU Takezako, Naoki

Results: 59
    1
    2

    Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.

    Published in:
    International Journal of Hematology, 2022, v. 116, n. 1, p. 89, doi. 10.1007/s12185-022-03334-8
    By:
    • Yoshida, Chikashi;
    • Kondo, Takeshi;
    • Ito, Tomoki;
    • Kizaki, Masahiro;
    • Yamamoto, Kazuhiko;
    • Miyamoto, Toshihiro;
    • Morita, Yasuyoshi;
    • Eto, Tetsuya;
    • Katsuoka, Yuna;
    • Takezako, Naoki;
    • Uoshima, Nobuhiko;
    • Imada, Kazunori;
    • Ando, Jun;
    • Komeno, Takuya;
    • Mori, Akio;
    • Ishikawa, Yuichi;
    • Satake, Atsushi;
    • Watanabe, Junichi;
    • Kawakami, Yoshiko;
    • Morita, Tetsuo
    Publication type:
    Article
    3

    Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.

    Published in:
    International Journal of Hematology, 2021, v. 113, n. 2, p. 219, doi. 10.1007/s12185-020-03013-6
    By:
    • Takezako, Naoki;
    • Shibayama, Hirohiko;
    • Handa, Hiroshi;
    • Hagiwara, Shotaro;
    • Ozaki, Shuji;
    • Suzuki, Kenshi;
    • Kosugi, Hiroshi;
    • Ri, Masaki;
    • Sugiura, Isamu;
    • Choi, Ilseung;
    • Miyamoto, Toshihiro;
    • Iida, Shinsuke
    Publication type:
    Article
    4

    Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.

    Published in:
    International Journal of Hematology, 2020, v. 112, n. 5, p. 640, doi. 10.1007/s12185-020-02953-3
    By:
    • Takezako, Naoki;
    • Kosugi, Hiroshi;
    • Matsumoto, Morio;
    • Iida, Shinsuke;
    • Ishikawa, Takayuki;
    • Kondo, Yukio;
    • Ando, Kiyoshi;
    • Miki, Hirokazu;
    • Matsumura, Itaru;
    • Sunami, Kazutaka;
    • Teshima, Takanori;
    • Iwasaki, Hiromi;
    • Onishi, Yasushi;
    • Kizaki, Masahiro;
    • Izutsu, Koji;
    • Maruyama, Dai;
    • Tobinai, Kensei;
    • Ghori, Razi;
    • Farooqui, Mohammed;
    • Liao, Jason
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15

    Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission.

    Published in:
    Cancer Science, 2020, v. 111, n. 8, p. 2923, doi. 10.1111/cas.14518
    By:
    • Kumagai, Takashi;
    • Nakaseko, Chiaki;
    • Nishiwaki, Kaichi;
    • Yoshida, Chikashi;
    • Ohashi, Kazuteru;
    • Takezako, Naoki;
    • Takano, Hina;
    • Kouzai, Yasuji;
    • Murase, Tadashi;
    • Matsue, Kosei;
    • Morita, Satoshi;
    • Sakamoto, Junichi;
    • Wakita, Hisashi;
    • Sakamaki, Hisashi;
    • Inokuchi, Koiti
    Publication type:
    Article
    16
    17

    Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.

    Published in:
    Cancer Science, 2018, v. 109, n. 1, p. 182, doi. 10.1111/cas.13430
    By:
    • Kumagai, Takashi;
    • Nakaseko, Chiaki;
    • Nishiwaki, Kaichi;
    • Yoshida, Chikashi;
    • Ohashi, Kazuteru;
    • Takezako, Naoki;
    • Takano, Hina;
    • Kouzai, Yasuji;
    • Murase, Tadashi;
    • Matsue, Kosei;
    • Morita, Satoshi;
    • Sakamoto, Junichi;
    • Wakita, Hisashi;
    • Sakamaki, Hisashi;
    • Inokuchi, Koiti;
    • the Kanto CML and Shimousa Hematology Study Groups
    Publication type:
    Article
    18
    19

    Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study.

    Published in:
    Cancer Science, 2016, v. 107, n. 5, p. 653, doi. 10.1111/cas.12916
    By:
    • Suzuki, Kenshi;
    • Shinagawa, Atsushi;
    • Uchida, Toshiki;
    • Taniwaki, Masafumi;
    • Hirata, Hirokazu;
    • Ishizawa, Kenichi;
    • Matsue, Kosei;
    • Ogawa, Yoshiaki;
    • Shimizu, Takayuki;
    • Otsuka, Maki;
    • Matsumoto, Morio;
    • Iida, Shinsuke;
    • Terui, Yasuhito;
    • Matsumura, Itaru;
    • Ikeda, Takashi;
    • Takezako, Naoki;
    • Ogaki, Yumi;
    • Midorikawa, Shuichi;
    • Houck, Vanessa;
    • Ervin‐Haynes, Annette
    Publication type:
    Article
    20

    Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.

    Published in:
    American Journal of Hematology, 2015, v. 90, n. 9, p. 819, doi. 10.1002/ajh.24096
    By:
    • Iriyama, Noriyoshi;
    • Fujisawa, Shin;
    • Yoshida, Chikashi;
    • Wakita, Hisashi;
    • Chiba, Shigeru;
    • Okamoto, Shinichiro;
    • Kawakami, Kimihiro;
    • Takezako, Naoki;
    • Kumagai, Takashi;
    • Inokuchi, Koiti;
    • Ohyashiki, Kazuma;
    • Taguchi, Jun;
    • Yano, Shingo;
    • Igarashi, Tadahiko;
    • Kouzai, Yasuji;
    • Morita, Satoshi;
    • Sakamoto, Junichi;
    • Sakamaki, Hisashi
    Publication type:
    Article
    21

    Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.

    Published in:
    American Journal of Hematology, 2015, v. 90, n. 4, p. 282, doi. 10.1002/ajh.23923
    By:
    • Iriyama, Noriyoshi;
    • Fujisawa, Shin;
    • Yoshida, Chikashi;
    • Wakita, Hisashi;
    • Chiba, Shigeru;
    • Okamoto, Shinichiro;
    • Kawakami, Kimihiro;
    • Takezako, Naoki;
    • Kumagai, Takashi;
    • Inokuchi, Koiti;
    • Ohyashiki, Kazuma;
    • Taguchi, Jun;
    • Yano, Shingo;
    • Igarashi, Tadahiko;
    • Kouzai, Yasuji;
    • Morita, Satoshi;
    • Sakamoto, Junichi;
    • Sakamaki, Hisashi
    Publication type:
    Article
    22
    23

    Clinical Features of Disseminated Intravascular Coagulation According to the French-American-British Classification in Patients With Acute Leukemia and Thrombomodulin Alfa Treatment—A Cohort Study Using a Postmarketing Surveillance Database.

    Published in:
    Clinical & Applied Thrombosis/Hemostasis, 2021, v. 27, p. 1, doi. 10.1177/10760296211054094
    By:
    • Yoshinobu, Seki;
    • Honda, Goichi;
    • Kawano, Noriaki;
    • Uchiyama, Toshimasa;
    • Kawasugi, Kazuo;
    • Madoiwa, Seiji;
    • Takezako, Naoki;
    • Takayuki, Ikezoe;
    • Wada, Hideo
    Publication type:
    Article
    24
    25

    Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 11, p. 1, doi. 10.1038/s41408-020-00375-2
    By:
    • Kaufman, Jonathan L.;
    • Dimopoulos, Meletios A.;
    • White, Darrell;
    • Benboubker, Lotfi;
    • Cook, Gordon;
    • Leiba, Merav;
    • Morton, James;
    • Joy Ho, P.;
    • Kim, Kihyun;
    • Takezako, Naoki;
    • Moreau, Philippe;
    • Sutherland, Heather J.;
    • Magen, Hila;
    • Iida, Shinsuke;
    • Kim, Jin Seok;
    • Miles Prince, H.;
    • Cochrane, Tara;
    • Oriol, Albert;
    • Bahlis, Nizar J.;
    • Chari, Ajai
    Publication type:
    Article
    26

    Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network.

    Published in:
    Blood Cancer Journal, 2019, v. 9, n. 10, p. N.PAG, doi. 10.1038/s41408-019-0245-1
    By:
    • Soekojo, Cinnie Yentia;
    • Kim, Kihyun;
    • Huang, Shang-Yi;
    • Chim, Chor-Sang;
    • Takezako, Naoki;
    • Asaoku, Hideki;
    • Kimura, Hideo;
    • Kosugi, Hiroshi;
    • Sakamoto, Junichi;
    • Gopalakrishnan, Sathish Kumar;
    • Nagarajan, Chandramouli;
    • Wei, Yuan;
    • Moorakonda, Rajesh;
    • Lee, Shu Ling;
    • Lee, Je Jung;
    • Yoon, Sung-Soo;
    • Kim, Jin Seok;
    • Min, Chang Ki;
    • Lee, Jae-Hoon;
    • Durie, Brian
    Publication type:
    Article
    27
    28
    29
    30
    31
    32

    Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR- ABL1 transcripts by imatinib therapy.

    Published in:
    International Journal of Clinical Oncology, 2017, v. 22, n. 5, p. 972, doi. 10.1007/s10147-017-1141-y
    By:
    • Shiseki, Masayuki;
    • Yoshida, Chikashi;
    • Takezako, Naoki;
    • Ohwada, Akira;
    • Kumagai, Takashi;
    • Nishiwaki, Kaichi;
    • Horikoshi, Akira;
    • Fukuda, Tetsuya;
    • Takano, Hina;
    • Kouzai, Yasuji;
    • Tanaka, Junji;
    • Morita, Satoshi;
    • Sakamoto, Junichi;
    • Sakamaki, Hisashi;
    • Inokuchi, Koiti
    Publication type:
    Article
    33

    Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

    Published in:
    2018
    By:
    • Kasamatsu, Tetsuhiro;
    • Ozaki, Shuji;
    • Saitoh, Takayuki;
    • Konishi, Jun;
    • Sunami, Kazutaka;
    • Itagaki, Mitsuhiro;
    • Asaoku, Hideki;
    • Cho, Takaaki;
    • Handa, Hiroshi;
    • Hagiwara, Shotaro;
    • Wakayama, Toshio;
    • Negoro, Akiko;
    • Takezako, Naoki;
    • Harada, Naoko;
    • Kuroda, Yoshiaki;
    • Nakaseko, Chiaki;
    • Miyake, Takaaki;
    • Inoue, Nobumasa;
    • Hata, Hiroyuki;
    • Shimazaki, Chihiro
    Publication type:
    journal article
    34
    35
    36
    37
    38
    39
    40
    41
    42

    Prophylactic action of oral fluconazole against fungal infection in neutropenic patients.

    Published in:
    Cancer (0008543X), 2000, v. 89, n. 7, p. 1611, doi. 10.1002/1097-0142(20001001)89:7<1611::AID-CNCR27>3.0.CO;2-B
    By:
    • Kanda, Yoshinobu;
    • Yamamoto, Rie;
    • Chizuka, Aki;
    • Hamaki, Tamae;
    • Suguro, Miyuki;
    • Arai, Chiaki;
    • Matsuyama, Tomohiro;
    • Takezako, Naoki;
    • Miwa, Akiyoshi;
    • Kern, Wolfgang;
    • Kami, Masahiro;
    • Akiyama, Hideki;
    • Hirai, Hisamaru;
    • Togawa, Atsushi
    Publication type:
    Article
    43
    44

    A comparison of minimal residual disease detection in autografts among ASO‐qPCR, droplet digital PCR, and next‐generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation.

    Published in:
    British Journal of Haematology, 2018, v. 183, n. 4, p. 664, doi. 10.1111/bjh.15002
    By:
    • Takamatsu, Hiroyuki;
    • Wee, Rachel K.;
    • Zaimoku, Yoshitaka;
    • Murata, Ryoichi;
    • Zheng, Jianbiao;
    • Moorhead, Martin;
    • Carlton, Victoria E. H.;
    • Kong, Katherine A.;
    • Takezako, Naoki;
    • Ito, Shigeki;
    • Miyamoto, Toshihiro;
    • Yokoyama, Kenji;
    • Matsue, Kosei;
    • Sato, Tsutomu;
    • Kurokawa, Toshiro;
    • Yagi, Hideo;
    • Terasaki, Yasushi;
    • Ohata, Kinya;
    • Matsumoto, Morio;
    • Yoshida, Takashi
    Publication type:
    Article
    45

    Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.

    Published in:
    Oncology Reports, 2016, v. 36, n. 5, p. 2976, doi. 10.3892/or.2016.5110
    By:
    • MAKI HAGIHARA;
    • NORIYOSHI IRIYAMA;
    • CHIKASHI YOSHIDA;
    • HISASHI WAKITA;
    • SHIGERU CHIBA;
    • SHINICHIRO OKAMOTO;
    • KIMIHIRO KAWAKAMI;
    • NAOKI TAKEZAKO;
    • TAKASHI KUMAGAI;
    • KOITI INOKUCHI;
    • KAZUMA OHYASHIKI;
    • JUN TAGUCHI;
    • SHINGO YANO;
    • TADAHIKO IGARASHI;
    • YASUJI KOUZAI;
    • SATOSHI MORITA;
    • JUNICHI SAKAMOTO;
    • HISASHI SAKAMAKI
    Publication type:
    Article
    46

    Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa.

    Published in:
    Thrombosis Journal, 2021, v. 19, n. 1, p. 1, doi. 10.1186/s12959-021-00264-z
    By:
    • Kawasugi, Kazuo;
    • Wada, Hideo;
    • Honda, Goichi;
    • Kawano, Noriaki;
    • Uchiyama, Toshimasa;
    • Madoiwa, Seiji;
    • Takezako, Naoki;
    • Suzuki, Kei;
    • Seki, Yoshinobu;
    • Ikezoe, Takayuki;
    • Iba, Toshiaki;
    • Okamoto, Kohji
    Publication type:
    Article
    47
    48
    49
    50

    P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
    By:
    • Dimopoulos, Meletios-Athanasios;
    • Dytfeld, Dominik;
    • Grosicki, Sebastian;
    • Moreau, Philippe;
    • Takezako, Naoki;
    • Hori, Mitsuo;
    • Leleu, Xavier;
    • LeBlanc, Richard;
    • Suzuki, Kenshi;
    • Raab, Marc;
    • Richardson, Paul G.;
    • McKiver, Mihaela Popa;
    • Ying-Ming Jou;
    • David Yao;
    • Das, Prianka;
    • San-Miguel, Jesús F.
    Publication type:
    Article